Mgc human nbr2 sequence verified cdnas

shRNAs targeting human NBR2 (NM_005821.2-615s1c1, NM_005821.2-514s1c1) were purchased from Sigma (Note that these two shRNAs target splicing isoforms #1 and #3 of NBR2, while can still achieve good knockdown efficiency when measured by real time PCR primer set designed to detect all three splicing isoforms of NBR2). siRNA targeting AMPKα were purchased from Origene (SR303721, SR303722). All three splicing isoforms of NBR2 were obtained from Thermo Fisher Scientific (MGC human NBR2 sequence-verified cDNAs, clone ID: 6452095, 4339497, 4826858) and then were subcloned into Lentiviral vector pLVX (Clontech). AMPK α, AMPK β and AMPK γ entry plasmids were obtained from Human ORFeome V5.1 library. The entry clones were subsequently recombined into gateway-compatible destination expression vectors with Flag tag through LR Gateway Technology (Invitrogen). cDNA corresponding to 1–312 a.a. of AMPK α1 was cloned into entry vector, and was subsequently recombined into gateway-compatible destination expression vectors with V5 tag through LR Gateway Technology (Invitrogen). Active human AMPK α2 protein and active human AMPK α1+AMPK β1+AMPK γ1 protein were purchase form Abcam (ab79803, ab126916). 2-Deoxy-D-glucose and compound C were purchased from Sigma (D6134, P5499). A-769662 was purchased from LC laboratories (A-1803).